Steer Engineering Private Limited v. Glaxosmithkline Consumer Healthcare Holdings (US)LLC; Glaxosmithkline Consumer Healthcare (UK) IP Limited; Glaxosmithkline Consumer Healthcare (UK) Trading Limited; Smithkline Beecham Limited

In the high-stakes world of proprietary technology, a company can spend years perfecting a process — only to watch a global competitor allegedly walk away with it. But as Steer Engineering Private Limited discovered, having a legitimate claim is not the same as convincing a court to hit the pause button. This case is a masterclass in why interim injunctions are the hardest relief to win, and why appellate courts rarely second-guess a trial judge's discretion.

Steer Engineering Private Limited, the appellant, is a specialized engineering firm that developed proprietary extrusion technology used in the manufacturing of nutritional beverages. The company claimed that Glaxosmithkline Consumer Healthcare, the respondent and a global consumer healthcare heavyweight, had infringed upon its copyright and misappropriated its trade secrets tied to this extrusion technology. Believing its confidential know-how had been unlawfully accessed or replicated, Steer Engineering approached the court seeking an interim injunction — a temporary order that would freeze GSK's allegedly infringing activities while the underlying dispute was still being decided. When the trial court declined to grant that temporary relief, Steer Engineering escalated the matter by filing a commercial appeal before the High Court.

Steer Engineering argued that its extrusion technology was the product of significant investment, research, and confidential development, and that GSK's use of similar processes amounted to copyright infringement and trade secret misappropriation. The company pushed for an interim injunction on the grounds that allowing GSK to continue its operations during the pendency of the suit would cause irreparable harm to its competitive position and confidential know-how. On the other side, Glaxosmithkline Consumer Healthcare resisted the injunction, and the trial court ultimately sided against Steer Engineering's request for temporary relief. The core legal friction was not about whether infringement had occurred — it was about whether Steer Engineering had done enough, at this preliminary stage, to convince the court that such extraordinary interim relief was warranted.

The High Court dismissed Steer Engineering's commercial appeal, ruling in favor of Glaxosmithkline Consumer Healthcare. The court found that the appellant had failed to establish a prima facie case — the foundational threshold of merit that a party must cross before a court will grant temporary relief. Without that threshold met, there was no legal basis to overturn the trial court's refusal to grant an interim injunction. The appellate court reaffirmed a critical principle: it will not lightly interfere with a trial court's discretionary order on temporary injunctions unless that order is shown to be perverse or illegal. The outcome left Steer Engineering without the immediate protection it sought, while GSK was free to continue its operations pending the resolution of the underlying dispute.

For founders and IP professionals, this case delivers a sobering reminder: interim injunctions are not granted on suspicion or potential — they require a clear, demonstrable prima facie case. If you believe your trade secrets or copyrighted technology have been stolen, do not wait. Delay in filing can undermine your claim to equitable relief, because courts look unfavorably on parties who sit on their rights while the alleged infringer continues to operate. Equally important, understand that appellate courts give wide latitude to trial judges on discretionary matters like temporary injunctions. Your best strategy is to build airtight evidence of ownership, confidentiality, and infringement from day one — so that when you walk into court asking for emergency relief, you are not walking in empty-handed.